TCRX News

After a slow start to the month, the IPO market revved back to life with 13 IPOs coming to market this past week. SPAC activity picked up, with seven blank check IPOs raising $940 million. New filers continued to flood the IPO pipeline, with fourteen IPOs and nine SPACs submitting initial filings.   Italian drug container supplier Stevanato Group (STVN)...read more

TScan Therapeutics, a preclinical biotech developing engineered T cell cancer therapies, raised $100 million by offering 6.7 million shares at $15, the low end of the range of $15 to $17. The company had previously filed to offer 6.3 million shares, but increased the share offering to maintain its original deal size. At pricing, TScan commands a fully diluted market value of $384...read more

TScan Therapeutics, a preclinical biotech developing engineered T cell cancer therapies, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, TScan Therapeutics would command a fully diluted market value of $404 million. TScan...read more

Updated Monday, 7/12. After a slow holiday week, 15 IPOs are scheduled to raise nearly $4 billion in the week ahead. A handful of SPACs should also price. Italian drug container supplier Stevanato Group (STVN) plans to raise $900 million at a $6.8 billion market cap. Controlled by its founding family, the profitable company supplies glass vials,...read more